{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:43:53Z","timestamp":1793241833138,"version":"4.5.0"},"reference-count":203,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.clml.2021.05.016","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T20:17:00Z","timestamp":1622319420000},"page":"580-597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades"],"prefix":"10.1016","volume":"21","author":[{"given":"Hagop M.","family":"Kantarjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.05.016_bib0001","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.05.016_bib0002","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaoncol.2015.0617","article-title":"Toward individualized therapy in acute myeloid leukemia: a contemporary review","volume":"1","author":"Kadia","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0003","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia\u2014current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.clml.2021.05.016_bib0004","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0005","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0006","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0007","doi-asserted-by":"crossref","unstructured":"Sasaki K, Ravandi F, Kadia TM, et\u00a0al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017.[e-pub ahead of print]. Cancer doi:10.1002\/cncr.33458.","DOI":"10.1002\/cncr.33458"},{"key":"10.1016\/j.clml.2021.05.016_bib0008","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ajh.24767","article-title":"Early mortality and overall survival of acute myeloid leukemia based on facility type","volume":"92","author":"Bhatt","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.05.016_bib0009","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/cncr.31296","article-title":"Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute\u2013designated cancer centers in California","volume":"124","author":"Ho","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0010","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0011","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.2019001728","article-title":"Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period","volume":"134","author":"Juliusson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0012","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.16265","article-title":"Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor","volume":"188","author":"Derolf","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.05.016_bib0013","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-021-00435-1","article-title":"Mayo Clinic experience with 1,123 adults with acute myeloid leukemia","volume":"11","author":"Begna","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.05.016_bib0014","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/leu.2013.176","article-title":"Declining rates of treatment-related mortality in patients with newly-diagnosed AML given \u201cintense\u201d induction regimens: a report from SWOG and MD Anderson","volume":"28","author":"Othus","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.016_bib0015","doi-asserted-by":"crossref","first-page":"26340","DOI":"10.1073\/pnas.2014732117","article-title":"Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A","volume":"117","author":"Bill","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2021.05.016_bib0016","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0017","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0018","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non\u2013high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0019","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0020","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/ajh.23795","article-title":"Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia","volume":"89","author":"Borthakur","year":"2014","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0021","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2019-126014","article-title":"Fludarabine, cytarabine, G-CSF and gemtuzumab ozogamicin (FLAG-GO) regimen results in better molecular response and relapse-free survival in core binding factor acute myeloid leukemia than FLAG and idarubicin (FLAG-Ida)","volume":"134","author":"Borthakur","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0022","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0023","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0024","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clml.2015.11.016","article-title":"clofarabine plus low-dose cytarabine is as effective as and less toxic than intensive chemotherapy in elderly AML patients","volume":"16","author":"Takahashi","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.05.016_bib0026","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1002\/cncr.30883","article-title":"A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0027","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.clml.2013.03.017","article-title":"Homoharringtonine\/omacetaxine mepesuccinate: the long and winding road to Food and Drug Administration approval","volume":"13","author":"Kantarjian","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.05.016_bib0028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clml.2014.09.011","article-title":"Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies","volume":"15","author":"Kantarjian","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.05.016_bib0029","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U","article-title":"Homoharringtonine: history, current research, and future direction","volume":"92","author":"Kantarjian","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0030","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3390\/jcm8091437","article-title":"FLAMSA-RIC for stem cell transplation in patients with acute myeloid leukemia and myelodysplastic syndromes: a systematic review and meta-analysis","volume":"8","author":"Owattanapanich","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0031","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00432-015-2050-y","article-title":"Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation","volume":"142","author":"Pfrepper","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0032","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.3324\/haematol.2018.191361","article-title":"Phase 3 results for vosaroxin\/cytarabine in the subset of patients\u00a0=\u00a060 years old with refractory\/early relapsed acute myeloid leukemia","volume":"103","author":"Ravandi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.05.016_bib0033","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood.V98.13.3575","article-title":"Comparison of idarubicin\u00a0+\u00a0ara-C\u2013, fludarabine\u00a0+\u00a0ara-C\u2013, and topotecan\u00a0+\u00a0ara-C\u2013based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts","volume":"98","author":"Estey","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0034","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2009-06-229351","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse","volume":"114","author":"Giles","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0035","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.critrevonc.2007.09.008","article-title":"Clinically useful prognostic factors in acute myeloid leukemia","volume":"66","author":"Ferrara","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2021.05.016_bib0036","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clml.2021.05.016_bib0037","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0038","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0039","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3324\/haematol.12366","article-title":"Relapse and death during first remission in acute myeloid leukemia","volume":"93","author":"Yanada","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.05.016_bib0040","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and validation of a novel acute myeloid leukemia\u2014composite model to estimate risks of mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0041","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41408-017-0011-1","article-title":"Improved outcome for AML patients over the years 2000-2014","volume":"7","author":"Bertoli","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.05.016_bib0042","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.05.016_bib0043","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.05.016_bib0044","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2165\/00002512-200522110-00004","article-title":"Trends in the treatment of acute myeloid leukaemia in the elderly","volume":"22","author":"Lang","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clml.2021.05.016_bib0045","series-title":"National Comprehensive Cancer Network","year":"2021"},{"key":"10.1016\/j.clml.2021.05.016_bib0046","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0047","doi-asserted-by":"crossref","unstructured":"Short M, Tallman M, Pollyea D, Ravandi F, Kantarjian H. Optimizing risk stratification in acute myeloid leukemia: dynamic models for a dynamic therapeutic landscape. J Clin Oncol, in press, 2021.","DOI":"10.1200\/JCO.21.00067"},{"key":"10.1016\/j.clml.2021.05.016_bib0048","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1200\/JCO.2011.41.5505","article-title":"Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON\/SAKK Cooperative Group","volume":"31","author":"Groschel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0049","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0050","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2003-02-0434","article-title":"AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases","volume":"102","author":"Schoch","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0051","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0052","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0053","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","article-title":"Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts","volume":"37","author":"Angenendt","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0054","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1200\/JCO.2013.52.3480","article-title":"Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia","volume":"32","author":"Pastore","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0055","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0056","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD\u2013positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0057","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/leu.2008.375","article-title":"The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia","volume":"23","author":"Seifert","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.016_bib0058","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0059","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1080\/10428194.2017.1422864","article-title":"Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.05.016_bib0060","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cncr.32566","article-title":"Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia","volume":"126","author":"Sasaki","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0061","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2011.40.6652","article-title":"RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures","volume":"30","author":"Mendler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0062","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2011.35.4894","article-title":"Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia","volume":"29","author":"Thol","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0063","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study","volume":"24","author":"Paschka","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0064","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2005-04-1466","article-title":"KIT-D816 mutations in AML1-ETO\u2013positive AML are associated with impaired event-free and overall survival","volume":"107","author":"Schnittger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0065","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.bbmt.2015.10.023","article-title":"Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD","volume":"22","author":"Ho","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.016_bib0066","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0067","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137685","article-title":"A phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML. final results","volume":"136","author":"Pratz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0068","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0069","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0070","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0071","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"24","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0072","series-title":"Paper presented at: 62nd ASH Annual Meeting and Exposition; December 5-8","article-title":"The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is effective in AML patients: phase 1b results","author":"Sallman","year":"2020"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0073","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2019-131055","article-title":"Phase 2 results of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML)","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0074","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2019-125579","article-title":"APR-246 combined with azacitidine in TP53 mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia: a phase 2 study by the Groupe FrancoPhone des My\u00e9lodysplasies (GFM).","volume":"134","author":"Cluzeau","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0075","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J Clin Invest"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0076","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-134942","article-title":"Preliminary data on a phase 1\/2a first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0077","unstructured":"AACR. CICR spring 2020 newsletter [selected research highlights]. Available at: https:\/\/www.aacr.org\/wp-content\/uploads\/2020\/06\/CICR_Newsletter_June_2020.pdf. Accessed: March 9, 2021."},{"key":"10.1016\/j.clml.2021.05.016_bib0078","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/bloodadvances.2019000492","article-title":"Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGH10801","volume":"4","author":"Marcucci","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.05.016_bib0079","series-title":"Poster presented at: 25th EHA Annual Congress; June 11-14,","article-title":"Avapritinib induces responses in patients (PTS) with advanced systemic mastocytosis (ADVSM), regardless of prior midostaurin therapy","author":"Gotlib","year":"2020"},{"key":"10.1016\/j.clml.2021.05.016_bib0080","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ng.3756","article-title":"Precision oncology for acute myeloid leukemia using a knowledge bank approach","volume":"49","author":"Gerstung","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2021.05.016_bib0081","unstructured":"AML multistage predictions. Available at: https:\/\/cancer.sanger.ac.uk\/aml-multistage\/. Accessed: March 9, 2021."},{"key":"10.1016\/j.clml.2021.05.016_bib0082","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/ajh.25975","article-title":"Acute myeloid leukemia: 2021 update on risk-stratification and management","volume":"95","author":"Estey","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.05.016_bib0083","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"10","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.05.016_bib0084","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0085","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2014-05-577593","article-title":"Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time\u201d?","volume":"124","author":"Grimwade","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0086","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2015.9452","article-title":"Next-generation sequencing and detection of minimal residual disease in acute myeloid leukemia: ready for clinical practice?","volume":"314","author":"Pastore","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2021.05.016_bib0087","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cncr.30361","article-title":"Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia","volume":"123","author":"Ravandi","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0088","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0089","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","article-title":"Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy","volume":"27","author":"Grimwade","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0090","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0091","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0092","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Kronke","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0093","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation\u2013specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0094","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0095","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood-2015-07-627323","article-title":"Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia","volume":"126","author":"Halpern","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0096","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs fluconazole or intraconazole propylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0097","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-142559","article-title":"Breakthrough invasive fungal infections (blFl) are uncommon in patients with newly diagnosed acute leukemia receiving primary antifungal prophylaxis","volume":"136","author":"Rausch","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0098","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2019-130642","article-title":"Acute myeloid leukemia and antifungal prophylaxis era: compliance of AML centers, invasive fungal infection (IFI) classification, IFI incidence and AML outcomes from ALFA 2007-02 study","volume":"134","author":"Michallet","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0099","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.V41.4.489.489","article-title":"Acute promyelocytic leukemia: results of treatment by daunorubicin","volume":"41","author":"Bernard","year":"1973","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0100","first-page":"1269","article-title":"Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside","volume":"8","author":"Ghaddar","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.016_bib0101","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0002-9343(86)90617-0","article-title":"Acute promyelocytic leukemia: M. D. Anderson Hospital experience","volume":"80","author":"Kantarjian","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0102","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/1097-0142(19870401)59:7<1258::AID-CNCR2820590705>3.0.CO;2-G","article-title":"Role of maintenance chemotherapy in acute promyelocytic leukemia","volume":"59","author":"Kantarjian","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0103","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.1985.3.6.793","article-title":"A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia","volume":"3","author":"Kantarjian","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0104","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","article-title":"Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia","volume":"72","author":"Huang","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0105","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1200\/JCO.2010.28.5031","article-title":"Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data","volume":"28","author":"Mathews","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0106","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2010.32.2107","article-title":"Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia","volume":"29","author":"Ghavamzadeh","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0107","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1182\/blood-2004-04-1550","article-title":"Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia","volume":"104","author":"Lo-Coco","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0108","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V94.4.1192","article-title":"A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: the European APL Group","volume":"94","author":"Fenaux","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0109","first-page":"3015","article-title":"A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML\/RARalpha\u2013positive acute promyelocytic leukemia: PETHEMA group","volume":"94","author":"Sanz","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0110","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-02-0632","article-title":"All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol","volume":"100","author":"Tallman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0111","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","article-title":"Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710","volume":"116","author":"Powell","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0112","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1182\/blood-2010-08-302950","article-title":"AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance","volume":"117","author":"Avvisati","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0113","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2001-12-0174","article-title":"Experience with gemtuzumab ozogamycin (\u201cmylotarg\u201d) and all-trans retinoic acid in untreated acute promyelocytic leukemia","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0114","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2018-05-851824","article-title":"Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial","volume":"132","author":"Russell","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0115","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/bloodadvances.2019001278","article-title":"A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)","volume":"4","author":"Lancet","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.05.016_bib0116","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3324\/haematol.2019.229583","article-title":"Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders","volume":"105","author":"Ravandi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.05.016_bib0117","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0118","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/sj.leu.2404272","article-title":"Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia","volume":"20","author":"Tsimberidou","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.016_bib0119","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.32196","article-title":"Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia","volume":"125","author":"Chamoun","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0120","first-page":"1188","article-title":"Acute myeloid leukemia\u2014treatment and research outlook in 2021, and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2021.05.016_bib0121","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2004.07.012","article-title":"Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461","volume":"22","author":"Byrd","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0122","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1200\/JCO.1999.17.12.3767","article-title":"Patients with t(8;21) (q22:q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0123","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41375-018-0129-6","article-title":"Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia\u2014results of the AMLSG 11-08 trial","volume":"32","author":"Paschka","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.016_bib0124","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/cid\/ciz194","article-title":"Baseline chest computed tomography for early diagnosis of invasive pulmonary aspergillosis in hemato-oncological patients: a prospective cohort study","volume":"69","author":"Bitterman","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2021.05.016_bib0125","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0126","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1182\/blood.V122.21.2692.2692","volume":"122","author":"Park","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0127","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1200\/JCO.2010.33.7303","article-title":"Cytarabine dose of 36 g\/m\u00b2 compared with 12 g\/m\u00b2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study","volume":"29","author":"Schaich","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0128","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","article-title":"A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study","volume":"117","author":"Miyawaki","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0129","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","article-title":"Cytarabine dose for acute myeloid leukemia","volume":"364","author":"L\u00f6wenberg","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2012-07-444851","article-title":"Sense and nonsense of high-dose cytarabine for acute myeloid leukemia","volume":"121","author":"L\u00f6wenberg","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0131","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0132","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood.V122.21.66.66","article-title":"Induction therapy for AML patients with daunorubicin dose of 60 mg\/m2 and 90 mg\/m2 results in similar complete response rate, relapse-free and overall survival","volume":"122","author":"Devillier","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0133","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2141.1998.00948.x","article-title":"A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia: AML Collaborative Group","volume":"103","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.05.016_bib0134","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2009.23.2652","article-title":"Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study","volume":"28","author":"Pautas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2011.40.3642","article-title":"Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older","volume":"31","author":"Gardin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0136","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1200\/JCO.2008.20.6490","article-title":"Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10","volume":"27","author":"Mandelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0137","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.21543","article-title":"High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials","volume":"107","author":"Kern","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0138","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0139","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","article-title":"A randomized study of high-dose cytarabine in induction in acute myeloid leukemia","volume":"87","author":"Bishop","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0140","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","article-title":"High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial","volume":"32","author":"Willemze","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0141","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/bloodadvances.2018026625","article-title":"Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML","volume":"3","author":"Bassan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.05.016_bib0142","unstructured":"Garcia-Manero G, Othus M, Pagel JM, et\u00a0al. Standard versus high-dose cytarabine with or without vorinostat in acute myelogenous leukemia: results of SWOG 1203. Leukemia, in press."},{"key":"10.1016\/j.clml.2021.05.016_bib0143","first-page":"3005","article-title":"Saturation of 1-beta-d-arabinofuranosylcytosine 5\u2032-triphosphate accumulation in leukemia cells during high-dose 1-beta-d-arabinofuranosylcytosine therapy","volume":"47","author":"Plunkett","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2021.05.016_bib0144","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ajh.25057","article-title":"Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in CD33-positive AML: final results and long term outcome of a phase II multicenter clinical trial","volume":"93","author":"Candoni","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.05.016_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106318","article-title":"Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG +\/\u2212 Idarubicin versus 3\u00a0+\u00a07 (anthracycline\u00a0+\u00a0cytarabine)","volume":"93","author":"Solh","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.05.016_bib0146","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/cancers13010034","article-title":"Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of FLT3-ITD in NPM1 mutated AML, irrespectively of FLT3-ITD allelic burden","volume":"13","author":"Minetto","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2021.05.016_bib0147","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.leu.2403336","article-title":"Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia: multicenter, phase III study","volume":"18","author":"Holowiecki","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.016_bib0148","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","article-title":"Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study","volume":"30","author":"Holowiecki","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0149","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2015-08-662130","article-title":"Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients","volume":"127","author":"Libura","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0150","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0151","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003471","article-title":"Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.","volume":"135","author":"Fournier","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0152","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0153","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0154","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0155","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0156","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"L\u00fcbbert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0157","article-title":"Workshop on the clinical results with decitabine (5-aza-2\u2032-deoxycytidine) in hematologic malignancies","volume":"11","author":"Kantarjian","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.016_bib0158","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5-aza-2\u2032deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0159","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0160","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1158\/0008-5472.CAN-05-2385","article-title":"DNA methylation changes after 5-aza-2\u2032-deoxycytidine therapy in patients with leukemia","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2021.05.016_bib0161","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0162","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0163","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","article-title":"Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial","volume":"27","author":"Steensma","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0164","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0166","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Blum","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2021.05.016_bib0167","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0168","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-133855","article-title":"Clinical efficacy and safety of oral decitabine\/cedazuridine in 133 patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)","volume":"136","author":"Savona","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0169","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/cncr.22508","article-title":"Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0170","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","article-title":"Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia","volume":"120","author":"Quintas-Cardama","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0171","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","article-title":"Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial","volume":"5","author":"Kadia","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.05.016_bib0172","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/cncr.29367","article-title":"Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia","volume":"121","author":"Kadia","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.016_bib0173","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0174","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0175","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0176","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0177","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-134736","article-title":"A results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with IDH 1\/2 mutations","volume":"136","author":"Pollyea","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0178","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-134100","article-title":"Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with FLT3 mutations","volume":"136","author":"Konopleva","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0179","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-140182","article-title":"Outcomes in TP53-mutant acute myeloid leukemia with venetoclax and decitabine","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0180","first-page":"2647","article-title":"Venetoclax combined with cladribine\u00a0+\u00a0low dose AraC (LDAC) alternating with 5-azacytidine produces high rates of minimal residual disease (MRD) negative complete remissions (CR) in older patients with newly diagnosed acute myeloid leukemia (AML)","volume":"136","author":"Kadia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0181","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0182","doi-asserted-by":"crossref","unstructured":"DiNardo C, Lachowiez C, Takahashi K, et\u00a0al. Venetoclax combined with FLAG-IDA induction andconsolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021 May 27:JCO2003736. doi: 10.1200\/JCO.20.03736. Epub ahead of print","DOI":"10.1200\/JCO.20.03736"},{"key":"10.1016\/j.clml.2021.05.016_bib0183","article-title":"Venetoclax combined with cladribine+low dose AraC (LDAC) alternating with 5-azacytidine produces high rates of minimal residual disease (MRD) negative complete remissions (CR) in older patients with newly diagnosed acute myeloid leukemia (AML).","author":"Kadia","year":"2021","journal-title":"Lancet Hematology"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0184","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood-2018-99-117870","article-title":"Outcomes with subsequent FLT3-inhibitor (FLT3i) based therapies in FLT3-mutated (mu) patients (pts) refractory\/relapsed (R\/R) to one or more prior FLT3 inhibitor based therapies: a single center experience","volume":"132","author":"Alfayez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0185","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0186","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0187","article-title":"(gilteritinib) in combination with azacitidine did not meet endpoint of overall survival in newly diagnosed FLT3 mutation\u2013positive acute myeloid leukemia patients ineligible for intensive induction chemotherapy [press release]","year":"2020","journal-title":"Astellas Pharma Inc;"},{"key":"10.1016\/j.clml.2021.05.016_bib0188","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.leukres.2018.03.006","article-title":"Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD\u2013mutated acute myeloid leukemia","volume":"68","author":"Choi","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.05.016_bib0189","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.V126.23.323.323","article-title":"Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1\/2 trial","volume":"126","author":"Stein","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0190","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0191","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood-2019-130362","volume":"134","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0192","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0193","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.05.016_bib0194","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients","volume":"133","author":"Huls","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0195","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.016_bib0196","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/2643-3230.BCD-20-0007","article-title":"Hedgehog pathway inhibitors: a new therapeutic class for the treatment of acute myeloid leukemia","volume":"1","author":"Jamieson","year":"2020","journal-title":"Blood Cancer Discovery"},{"key":"10.1016\/j.clml.2021.05.016_bib0197","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.016_bib0198","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.clml.2021.05.016_bib0199","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.clml.2021.05.016_bib0200","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","article-title":"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD\u2013mutated, relapsed or refractory AML","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0201","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1182\/blood-2018-99-114263","article-title":"Phase 1 study of the IDH1m inhibitor FT-2102 as a single agent in patients with IDH1m acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)","volume":"132","author":"Watts","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.016_bib0202","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.05.016_bib0203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-139903","article-title":"Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"136","author":"Pemmaraju","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:17Z","timestamp":1761870977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":203,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2152265021002032"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}